Active targeting compound, a non-iodinated derivative of IK-IK-I-azaBODIPY (1a) was previously reported to preferentially bind melanoma over healthy cells. In this study, we evaluate the photodynamic therapy (PDT) efficiency on melanoma cells of 1a, together with its reversed sequence compound KI-KI-I-azaBODIPY (1b) and a non-targeted control I-azaBODIPY-NH (2). All three test compounds possess absorption wavelengths in the near-infrared (NIR) region (λ between 678 and 687nm) which alleviate melanin interference and allow deeper tissue penetration. In vitro studies revealed 1a and 1b are promising photosensitizers with enhanced singlet oxygen generation, have increased uptake by B16-F10 melanoma cells via clathrin-mediated endocytosis and good photocytotoxic efficacies. Ex vivo biodistribution assays showed both 1a and 1b accumulated in the tumour. In B16-F10 tumour bearing-C57BL/6 mice, 10 mg/kg of 1b and light irradiation was found to reduce tumour volume by up to 23% at day-3. Doubling the dosage of 1b (20 mg/kg) enhanced the antitumour effect, showing 96% maximum tumour volume reduction at day-7 and tumour growth suppression for up to 12 days.Copyright © 2020. Published by Elsevier B.V.
Doxycycline decreases amyloidogenic light chain-induced autophagy in isolated primary cardiac myocytes.
July 20, 2020
March 20, 2020
Safety aspects of opioid-naïve patients with high-grade glioma treated with D,L-Methadone: an observational case series.
February 17, 2020
- AACR-2020The American Association for Cancer Research is the world's oldest and largest professional association related to cancer research.
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.